CVRx Barostim receives expanded CMS coverage — first neuromodulation therapy for heart failure broadens patient access

Summary

CVRx's Barostim — the first neuromodulation therapy approved for heart failure that electrically modulates the baroreceptor reflex to reduce heart workload — received expanded CMS coverage determination. The device uses the body's own nervous system to improve cardiac function without the chemical fatigue side effects of standard heart failure medications. Expanded coverage makes Barostim available to a larger Medicare heart failure population at participating centers.